Clinical data | |
---|---|
Other names | CORT-125134 |
Routes of administration | By mouth |
Drug class | Antiglucocorticoid |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C27H22F4N6O3S |
Molar mass | 586.57 g·mol−1 |
3D model ( JSmol) | |
| |
|
Relacorilant (developmental code name CORT-125134) is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. [1] It is also under development for the treatment of solid tumors and alcoholism. [1] [2] The drug is a nonsteroidal compound and acts as an antagonist of the glucocorticoid receptor. [1] As of December 2017, it is in phase II clinical trials for Cushing's syndrome and phase I/II clinical studies for solid tumors, while the clinical phase for alcoholism is unknown. [1]